Nutra Pharma's RPI-78M prevents onset of multiple sclerosis in animal tests, study says

By Angela McDaniels

Seattle, Dec. 20 - Nutra Pharma Corp. said RPI-78M, the lead drug candidate of subsidiary ReceptoPharm Inc., was very effective in preventing the onset of disability in acute and chronic animal models of multiple sclerosis during preclinical studies.

The drug also prevented infiltration of immune cells into the central nervous system, the company said.

This research was conducted to confirm the reported benefits of similar products in immune-mediated diseases such as multiple sclerosis and rheumatoid arthritis.

"The experimental allergic encephalomyelitis study yielded the results we expected, though we were pleasantly surprised at the reduced central nervous system infiltration by lymphocytes," ReceptoPharm chief executive officer Paul Reid said in a company news release.

"The results of this study complete the rationale for entering into clinical trials for the multiple sclerosis indication. We are actively working on one Investigational New Drug Application for the phase 2/3 adrenomyeloneuropathy indication, and when that is completed we will be in a good position to enter into multiple sclerosis trials."

The study was conducted by researchers at the University of Saskatchewan.

Nutra Pharma is a biopharmaceutical company based in Boynton Beach, Fla., that acquires, licenses and commercializes pharmaceutical products and technologies. Its subsidiary ReceptoPharm develops therapeutic proteins for the treatment of viral, autoimmune and neuro-degenerative disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.